Aktuellt
SENASTE
Earlier today, Vicore announced that it will add a new indication for C21, the rare lung disease pulmonary arterial hypertension (PAH), and start a proof-of-concept study by late 2022. PAH has a significant unmet medical need, as today’s treatments do not change the underlying disease, and Vicore states that promising pre-clinical data and the vascular effect showed in the mechanistic systemic sclerosis trial together call for further research into the indication. We are encouraged by the move and see a solid rationale. Vicore will host an R&D day tomorrow where we expect to learn more about the study and upcoming strategy.
LÄS MER
